YMAB — Y-mAbs Therapeutics Share Price
0.000.00%
Last trade - 00:00- $199.67m
- $132.44m
- $87.69m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.17 | ||
| Price to Tang. Book | 2.23 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.28 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -32.43% | ||
| Return on Equity | -30.74% | ||
| Operating Margin | -35.58% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 20.75 | 34.9 | 65.27 | 84.82 | 87.69 | 82.49 | 98.02 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Y-mAbs Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of radioimmunotherapy and antibody-based therapeutic cancer products. The Company’s technologies include its investigational Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform (PRIT), and bispecific antibodies generated using the Y-BiClone platform. Its advanced product pipeline includes the anti-GD2 therapy DANYELZA (naxitamab-gqgk), the first food and drug administration (FDA)-approved treatment for patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow after a partial response, minor response, or stable disease to prior therapy. DANYELZA is a humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody, or monoclonal antibody (mAb), that targets ganglioside GD2, which is expressed in various neuroectoderm derived tumors and sarcomas.
Directors
- Thomas Gad CHM (51)
- Claus Moller-San Pedro CEO (59)
- Bo Kruse CFO (49)
- Joris Wilms COO (47)
- Torben Lund-Hansen SVP (70)
- Steen Lisby SVP (57)
- Vignesh Rajah SVP (56)
- Sue Smith SVP (51)
- Gerard Ber IND (63)
- David Gill IND (66)
- Laura Hamill IND (56)
- James Healy IND (56)
- Ashutosh Tyagi IND (44)
- Johan Wedell-Wedellsborg IND (51)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- April 30th, 2015
- Public Since
- September 21st, 2018
- No. of Shareholders
- 6
- No. of Employees
- 107
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 45,276,915
- Address
- 202 Carnegie Center, Suite 301, PRINCETON, 08540
- Web
- https://www.ymabs.com/
- Phone
- +1 6468858505
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for YMAB
Q2 2025 Y-mAbs Therapeutics Inc Earnings Release
Similar to YMAB
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
FAQ
What is the Y-mAbs Therapeutics share price?
As of Today at 24:14 UTC, shares in Y-mAbs Therapeutics are trading at $4.41. This share price information is delayed by 15 minutes.
How has the Y-mAbs Therapeutics share price performed this year?
Shares in Y-mAbs Therapeutics last closed at $4.41 and the price had moved by -74.43% over the past 365 days. In terms of relative price strength the Y-mAbs Therapeutics share price has underperformed the S&P500 Index by -76.95% over the past year.
What are the analyst and broker recommendations for Y-mAbs Therapeutics?
The overall consensus recommendation for Y-mAbs Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Y-mAbs Therapeutics dividend yield?
Y-mAbs Therapeutics does not currently pay a dividend.
Does Y-mAbs Therapeutics pay a dividend?
Y-mAbs Therapeutics does not currently pay a dividend.
When does Y-mAbs Therapeutics next pay dividends?
Y-mAbs Therapeutics does not currently pay a dividend.
How do I buy Y-mAbs Therapeutics shares?
To buy shares in Y-mAbs Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Y-mAbs Therapeutics?
As of the previous close price of $4.41, shares in Y-mAbs Therapeutics had a market capitalisation of $199.67m.
Where are Y-mAbs Therapeutics shares listed?
Here are the trading details for Y-mAbs Therapeutics:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: YMAB
What kind of share is Y-mAbs Therapeutics?
Based on an overall assessment of its quality, value and momentum Y-mAbs Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Y-mAbs Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in Y-mAbs Therapeutics is $15.82. That is 258.73% above the last closing price of $4.41.
Analysts covering Y-mAbs Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$1.01 for the next financial year.
Find out moreWhat is the trend in the Y-mAbs Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Y-mAbs Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -69.94%.
As of the last closing price of $4.41, shares in Y-mAbs Therapeutics were trading -53.85% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Y-mAbs Therapeutics PE Ratio?
The Y-mAbs Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $4.41.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Y-mAbs Therapeutics?
Y-mAbs Therapeutics' management team is headed by:
- Thomas Gad - CHM
- Claus Moller-San Pedro - CEO
- Bo Kruse - CFO
- Joris Wilms - COO
- Torben Lund-Hansen - SVP
- Steen Lisby - SVP
- Vignesh Rajah - SVP
- Sue Smith - SVP
- Gerard Ber - IND
- David Gill - IND
- Laura Hamill - IND
- James Healy - IND
- Ashutosh Tyagi - IND
- Johan Wedell-Wedellsborg - IND